PreMD Announces FDA Decision on POC Skin Cholesterol Test

    Company to Immediately Address FDA Ruling

    TORONTO, Jan. 15 /CNW/ - Predictive medicine company PreMD Inc. (TSX:
PMD; Amex:   PME) announced today that it has received a non-substantially
equivalent (NSE) letter from the U.S. Food and Drug Administration (FDA)
regarding the 510(k) submission for an expanded regulatory claim on its
point-of-care (POC) skin cholesterol test. The company expects to evaluate its
options as part of the plans to address this issue.
    "We are very disappointed with this decision by the FDA regarding our
510(k) submission. We believe we have provided adequate information to support
clearance and continue to believe that our product merits clearance by the
FDA," said Brent Norton, president and chief executive officer of PreMD. "The
company is pursuing the next steps in addressing the decision and we will work
through the process as expeditiously as possible. We continue to believe that
this test fulfills a need for screening asymptomatic patients for risk of
cardiovascular disease. Furthermore, our recent clinical achievements such as
our presentation at the American Heart Association and scheduled publication
in the American Journal of Cardiology for April show that we are supported in
our belief of the strength of our product. The company has adequate cash to
support operations through the near term. However, we will continue to
evaluate and decrease spending throughout the organization to ensure our
ability to execute the necessary tasks."
    The FDA's primary grounds for rejecting the claim relate to the clinical
utility of evaluating skin cholesterol with carotid wall intima thickness
(CIMT) as the clinical endpoint. PreMD submitted the 510(k) application to the
FDA in June 2007 based on a study design that was previously accepted as
appropriate by the FDA. Subsequently, the FDA requested additional information
regarding statistical clarification on the data submitted. The company
promptly provided the information requested and believes that it addressed
those concerns to the best capabilities of the company. PreMD was not aware of
the FDA's issue or concerns from previous discussions.

    About PreMD Inc.

    PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products include a line of non-invasive skin
cholesterol tests, planned to be marketed and distributed by AstraZeneca
Pharmaceuticals. PreMD's other skin cholesterol products include PREVU(*) LT, a
skin cholesterol test designed for use in the life insurance industry. The
company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast
cancer test. PreMD's head office is located in Toronto, Ontario and its
research and product development facility is at McMaster University in
Hamilton, Ontario. For more information about PreMD, please visit

    This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the success of a plan for regaining compliance with certain continued
listing standards of the American Stock Exchange, successful development or
marketing of the Company's products, the competitiveness of the Company's
products if successfully commercialized, the lack of operating profit and
availability of funds and resources to pursue R&D projects, the successful and
timely completion of clinical studies, product liability, reliance on
third-party manufacturers, the ability of the Company to take advantage of
business opportunities, uncertainties related to the regulatory process, and
general changes in economic conditions.
    In addition, while the Company routinely obtains patents for its products
and technology, the protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by our competitors
and there can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates. Investors should consult
the Company's quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and uncertainties
relating to the forward-looking statements. Investors are cautioned not to
rely on these forward-looking statements. PreMD is providing this information
as of the date of this press release and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise.

    (*) Trademark

    %SEDAR: 00007927E          %CIK: 0001179083

For further information:

For further information: Brent Norton, President and CEO, Tel: (416)
222-3449 ext. 22, Email:; Ron Hosking, Vice President
Finance and CFO, Tel: (416) 222-3449 ext. 24, Email:;
Michelle Rabba, Manager, Corporate Communications, Tel: (416) 222-3449 ext.
25, Email:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890